LENSAR is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Co.'s existing LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility. Co. is also designing, developing, and seeking regulatory clearance of a system, its ALLY Adaptive Cataract Treatment System, which combines an improved femtosecond laser with a phacoemulsification system in a single, integrated cataract treatment system. The LNSR average annual return since 2020 is shown above.
The Average Annual Return on the LNSR average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LNSR average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LNSR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|